Micardis® in Patients With Essential Hypertension
Information source: Boehringer Ingelheim
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Hypertension
Intervention: Telmisartan tablets (Drug)
Phase: Phase 4
Status: Completed
Sponsored by: Boehringer Ingelheim
Summary
The aim of this observational study was to supplement the data on efficacy, safety, and
tolerability of telmisartan under daily conditions in hospitals
Clinical Details
Official title: Observation of Therapy With Micardis® (Telmisartan) in Patients With Essential Hypertension in Hospitals
Study design: Observational Model: Cohort, Time Perspective: Prospective
Primary outcome: Changes from baseline in blood pressureNumber of patients with adverse events
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Patients with essential hypertension
- Minimum age of 18 years
Exclusion Criteria: Not applicable
Locations and Contacts
Additional Information
Starting date: May 1999
Last updated: July 10, 2014
|
